The fibrinogen prothrombin time‐derived method is not useful in patients anticoagulated with low molecular weight heparins or rivaroxaban
Essentials Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied. FIBPT‐d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples. Unfractionated heparin and dabigatran samples showed similar bias to the control group. Rabb...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis Jg. 16; H. 8; S. 1626 - 1631 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Limited
01.08.2018
|
| Schlagworte: | |
| ISSN: | 1538-7933, 1538-7836, 1538-7836 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Essentials
Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied.
FIBPT‐d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples.
Unfractionated heparin and dabigatran samples showed similar bias to the control group.
Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.
Summary
Background
The fibrinogen prothrombin time‐derived (FIBPT‐d) method with photo‐optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH).
Objective
To compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT‐d method with two thromboplastins in anticoagulated patients.
Population
The study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs).
Methods
Dabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL−1 reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT‐d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT‐d method versus the FIB C method were calculated by the use of Bland–Altman plots.
Results
Positive biases of the FIBPT‐d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples.
Conclusion
The FIBPT‐d method should not be used in anticoagulated patients, because the FIBPT‐d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients. |
|---|---|
| AbstractList | Essentials
Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied.
FIBPT‐d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples.
Unfractionated heparin and dabigatran samples showed similar bias to the control group.
Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.
Summary
Background
The fibrinogen prothrombin time‐derived (FIBPT‐d) method with photo‐optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH).
Objective
To compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT‐d method with two thromboplastins in anticoagulated patients.
Population
The study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs).
Methods
Dabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL−1 reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT‐d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT‐d method versus the FIB C method were calculated by the use of Bland–Altman plots.
Results
Positive biases of the FIBPT‐d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples.
Conclusion
The FIBPT‐d method should not be used in anticoagulated patients, because the FIBPT‐d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients. BackgroundThe fibrinogen prothrombin time‐derived (FIBPT‐d) method with photo‐optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH).ObjectiveTo compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT‐d method with two thromboplastins in anticoagulated patients.PopulationThe study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs).MethodsDabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL−1 reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT‐d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT‐d method versus the FIB C method were calculated by the use of Bland–Altman plots.ResultsPositive biases of the FIBPT‐d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples.ConclusionThe FIBPT‐d method should not be used in anticoagulated patients, because the FIBPT‐d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients. Essentials Fibrinogen prothrombin time-derived (FIBPT-d) behavior in anticoagulated patients is under studied. FIBPT-d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples. Unfractionated heparin and dabigatran samples showed similar bias to the control group. Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.Essentials Fibrinogen prothrombin time-derived (FIBPT-d) behavior in anticoagulated patients is under studied. FIBPT-d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples. Unfractionated heparin and dabigatran samples showed similar bias to the control group. Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.Background The fibrinogen prothrombin time-derived (FIBPT-d) method with photo-optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH). Objective To compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT-d method with two thromboplastins in anticoagulated patients. Population The study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs). Methods Dabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL-1 reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT-d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT-d method versus the FIB C method were calculated by the use of Bland-Altman plots. Results Positive biases of the FIBPT-d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples. Conclusion The FIBPT-d method should not be used in anticoagulated patients, because the FIBPT-d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients.SUMMARYBackground The fibrinogen prothrombin time-derived (FIBPT-d) method with photo-optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH). Objective To compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT-d method with two thromboplastins in anticoagulated patients. Population The study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs). Methods Dabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL-1 reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT-d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT-d method versus the FIB C method were calculated by the use of Bland-Altman plots. Results Positive biases of the FIBPT-d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples. Conclusion The FIBPT-d method should not be used in anticoagulated patients, because the FIBPT-d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients. Essentials Fibrinogen prothrombin time-derived (FIBPT-d) behavior in anticoagulated patients is under studied. FIBPT-d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples. Unfractionated heparin and dabigatran samples showed similar bias to the control group. Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples. Background The fibrinogen prothrombin time-derived (FIBPT-d) method with photo-optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH). Objective To compare fibrinogen results obtained with the Clauss (FIB C) method and the FIBPT-d method with two thromboplastins in anticoagulated patients. Population The study population comprised 295 consecutive anticoagulated patients: 99 treated with vitamin K antagonists (VKAs), 49 treated with unfractionated heparin (UFH), 47 treated with LMWH, 50 treated with rivaroxaban, 50 treated with dabigatran, and 100 normal controls (NCs). Methods Dabigatran samples were analyzed by the use of FIB C with HemosIL Fibrinogen C or 100 NHI thrombin units mL reagents; rabbit brain and human recombinant thromboplastins with HemosIL PTFibrinogen HS plus (HS) and Recombiplastin 2G (RP) were used for FIBPT-d method. Heparin and rivaroxaban levels were assessed with HemosIL Liq antiXa with specific calibrators; dabigatran levels were determined with the HemosIL Direct Thrombin Inhibitor Assay. All assays were performed on the ACL TOP platform in two laboratories. Percentage biases for the FIBPT-d method versus the FIB C method were calculated by the use of Bland-Altman plots. Results Positive biases of the FIBPT-d method versus the FIB C method with both thromboplastins were seen in NC samples (13.7% and 18.9% for HS and RP, respectively), but biases with HS in rivaroxaban and VKA patient samples were higher than that in NC samples, at 31.9% and 34.0%, respectively. LMWH patient samples showed higher bias than NC samples: 26.5% and 29.3.0% with HS and RP, respectively. UFH and dabigatran patient samples showed similar bias as NC samples. Conclusion The FIBPT-d method should not be used in anticoagulated patients, because the FIBPT-d mathematical algorithm has been validated only in normal subjects, so overestimation could occur in these patients. |
| Author | Lopez, M. Martinuzzo, M. E. Oyhamburu, J. Barrera, L. Duboscq, C. Ceresetto, J. Stemmelin, G. |
| Author_xml | – sequence: 1 givenname: C. surname: Duboscq fullname: Duboscq, C. email: cduboscq@hbritanico.com, cduboscq58@hotmail.com organization: Servcio de Hematología Hospital Británico de Buenos Aires – sequence: 2 givenname: M. E. surname: Martinuzzo fullname: Martinuzzo, M. E. organization: Instituto Universitario Hospital Italiano – sequence: 3 givenname: J. surname: Ceresetto fullname: Ceresetto, J. organization: Servcio de Hematología Hospital Británico de Buenos Aires – sequence: 4 givenname: M. surname: Lopez fullname: Lopez, M. organization: Instituto Universitario Hospital Italiano – sequence: 5 givenname: L. surname: Barrera fullname: Barrera, L. organization: Instituto Universitario Hospital Italiano – sequence: 6 givenname: J. surname: Oyhamburu fullname: Oyhamburu, J. organization: Instituto Universitario Hospital Italiano – sequence: 7 givenname: G. surname: Stemmelin fullname: Stemmelin, G. organization: Servcio de Hematología Hospital Británico de Buenos Aires |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29790645$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90TtvFDEQAGALBZEHFPwBZIkGikv82IddoggIKBLNUa9s7_jWJ6992N4c6ehp-I38EgyXUEQCN7asb2bsmVN0FGIAhJ5Tck7rutiW6Zw2tBWP0AltuVj1gndH92fJ-TE6zXlLCJUtI0_QMZO9JF3TnqDv6wmwdTq5EDcQ8C7FMqU4axdwcTP8_PZjhORuYMQzlCmO2GUcYsFLBrt4XNlOFQehZKxCcSaqzeJVqX7vyoR93OM5ejD1MuE9uM1U8AQ7VQtmHBOuuVWKX5VW4Sl6bJXP8OxuP0Of371dX16trj-9_3D55npluBBiJbmRrLGsUXzsW8Ekaztqxt5YPbbAG9UJqhvJtLWNYaTThtrOWtnaToPqKD9Drw5562e_LJDLMLtswHsVIC55YKThtG9E31f68gHdxiWF-rqqBOWMSyKrenGnFj3DOOySm1W6He7bXMHrAzAp5pzA_iWUDL9HONQRDn9GWO3FA2tcqS2OoSTl_P8i9s7D7b9TDx_XV4eIX52YsHw |
| CitedBy_id | crossref_primary_10_1016_j_thromres_2024_01_017 crossref_primary_10_1111_ijlh_14201 |
| Cites_doi | 10.1016/j.thromres.2004.05.008 10.1055/s-0036-1579636 10.1097/00001721-199412000-00012 10.1097/00001721-199804000-00006 10.1097/00001721-200201000-00010 10.1160/TH10-10-0667 10.1016/j.thromres.2010.09.004 10.1046/j.1365-2141.2003.04256.x 10.1160/TH14-02-0161 |
| ContentType | Journal Article |
| Copyright | 2018 International Society on Thrombosis and Haemostasis 2018 International Society on Thrombosis and Haemostasis. Copyright © 2018 International Society on Thrombosis and Haemostasis |
| Copyright_xml | – notice: 2018 International Society on Thrombosis and Haemostasis – notice: 2018 International Society on Thrombosis and Haemostasis. – notice: Copyright © 2018 International Society on Thrombosis and Haemostasis |
| DBID | AAYXX CITATION NPM 7T5 H94 K9. 7X8 |
| DOI | 10.1111/jth.14158 |
| DatabaseName | CrossRef PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7836 |
| EndPage | 1631 |
| ExternalDocumentID | 29790645 10_1111_jth_14158 JTH14158 |
| Genre | shortCommunication Journal Article |
| GroupedDBID | --- 05W 1OC 24P 29L 2WC 31~ 33P 36B 3SF 4.4 52U 52V 53G 5GY 5VS 66C 8-0 8-1 A00 AAESR AAEVG AAHHS AALRI AAONW AASGY AAXRX AAXUO AAZKR ABCUV ABDBF ABJNI ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADVLN ADXAS ADZMN AEEZP AEIMD AENEX AEQDE AFBPY AFEBI AFGKR AFJKZ AFPWT AFZJQ AHMBA AIACR AITUG AIURR AIWBW AJAOE AJBDE AKRWK ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMRAJ AMYDB ATUGU AZBYB AZVAB BAWUL BHBCM BMXJE BOGZA BRXPI C45 CAG COF CS3 DCZOG DIK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBS EJD EMB EMK ESX F5P FDB FIJ FUBAC G-S GODZA HZ~ IHE IPNFZ IX1 KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES M41 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ ROL SUPJJ SV3 TEORI TR2 W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WVDHM WYJ ZZTAW AAMMB AAYWO AAYXX ACVFH ADCNI AEFGJ AEUPX AFPUW AGXDD AIDQK AIDYY AIGII AKBMS AKYEP APXCP CITATION EFKBS AGCQF NPM 7T5 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c3888-93c924f24a3d758292561cd7cfbd5e34a681b492bff4c206bc1f6ff95f6bea613 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000440553400020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-7933 1538-7836 |
| IngestDate | Thu Oct 02 11:59:29 EDT 2025 Tue Oct 07 06:07:19 EDT 2025 Thu Sep 18 02:45:09 EDT 2025 Wed Oct 29 21:10:26 EDT 2025 Tue Nov 18 22:26:50 EST 2025 Wed Jan 22 16:59:10 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | heparin low molecular weight dabigatran rivaroxaban fibrinogen analysis blood coagulation tests |
| Language | English |
| License | 2018 International Society on Thrombosis and Haemostasis. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3888-93c924f24a3d758292561cd7cfbd5e34a681b492bff4c206bc1f6ff95f6bea613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jth.14158 |
| PMID | 29790645 |
| PQID | 2081323909 |
| PQPubID | 1086376 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2043174877 proquest_journals_2081323909 pubmed_primary_29790645 crossref_primary_10_1111_jth_14158 crossref_citationtrail_10_1111_jth_14158 wiley_primary_10_1111_jth_14158_JTH14158 |
| PublicationCentury | 2000 |
| PublicationDate | August 2018 |
| PublicationDateYYYYMMDD | 2018-08-01 |
| PublicationDate_xml | – month: 08 year: 2018 text: August 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | Journal of thrombosis and haemostasis |
| PublicationTitleAlternate | J Thromb Haemost |
| PublicationYear | 2018 |
| Publisher | Elsevier Limited |
| Publisher_xml | – name: Elsevier Limited |
| References | 2016; 42 2008 2004; 114 2011; 106 2015; 113 1994; 5 2003; 121 2002; 13 2010; 126 1998; 9 Van Blerk (10.1111/jth.14158_bb0045) 2015; 113 De Cristofaro (10.1111/jth.14158_bb0025) 1998; 9 Mani (10.1111/jth.14158_bb0050) 2011; 106 10.1111/jth.14158_bb0055 Sobas (10.1111/jth.14158_bb0035) 2002; 13 Llamas (10.1111/jth.14158_bb0020) 2004; 114 Miesbach (10.1111/jth.14158_bb0040) 2010; 126 Mackie (10.1111/jth.14158_bb0015) 2003; 121 Undas (10.1111/jth.14158_bb0010) 2016; 42 Chitolie (10.1111/jth.14158_bb0030) 1994; 5 |
| References_xml | – volume: 126 start-page: e428 year: 2010 end-page: 33 article-title: Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia publication-title: Thromb Res – volume: 42 start-page: 381 year: 2016 end-page: 8 article-title: How to assess fibrinogen levels and fibrin clot properties in clinical practice? publication-title: Semin Thromb Hemost – volume: 13 start-page: 61 year: 2002 end-page: 8 article-title: Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation publication-title: Blood Coagul Fibrinolysis – volume: 106 start-page: 156 year: 2011 end-page: 64 article-title: Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time publication-title: Thromb Haemost – volume: 121 start-page: 396 year: 2003 end-page: 404 article-title: Guidelines on fibrinogen assays publication-title: Br J Haematol – volume: 5 start-page: 955 year: 1994 end-page: 7 article-title: Inaccuracy of the ‘derived’ fibrinogen measurement publication-title: Blood Coagul Fibrinolysis – volume: 114 start-page: 73 year: 2004 end-page: 4 article-title: Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method publication-title: Thromb Res – year: 2008 – volume: 9 start-page: 251 year: 1998 end-page: 60 article-title: Measurement of plasma fibrinogen concentration by the prothrombin‐time‐derived method publication-title: Blood Coagul Fibrinolysis – volume: 113 start-page: 154 year: 2015 end-page: 64 article-title: Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey publication-title: Thromb Haemost – volume: 114 start-page: 73 year: 2004 ident: 10.1111/jth.14158_bb0020 article-title: Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method publication-title: Thromb Res doi: 10.1016/j.thromres.2004.05.008 – volume: 42 start-page: 381 year: 2016 ident: 10.1111/jth.14158_bb0010 article-title: How to assess fibrinogen levels and fibrin clot properties in clinical practice? publication-title: Semin Thromb Hemost doi: 10.1055/s-0036-1579636 – volume: 5 start-page: 955 year: 1994 ident: 10.1111/jth.14158_bb0030 article-title: Inaccuracy of the ‘derived’ fibrinogen measurement publication-title: Blood Coagul Fibrinolysis doi: 10.1097/00001721-199412000-00012 – volume: 9 start-page: 251 year: 1998 ident: 10.1111/jth.14158_bb0025 article-title: Measurement of plasma fibrinogen concentration by the prothrombin‐time‐derived method publication-title: Blood Coagul Fibrinolysis doi: 10.1097/00001721-199804000-00006 – volume: 13 start-page: 61 year: 2002 ident: 10.1111/jth.14158_bb0035 article-title: Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation publication-title: Blood Coagul Fibrinolysis doi: 10.1097/00001721-200201000-00010 – volume: 106 start-page: 156 year: 2011 ident: 10.1111/jth.14158_bb0050 article-title: Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time publication-title: Thromb Haemost doi: 10.1160/TH10-10-0667 – volume: 126 start-page: e428 year: 2010 ident: 10.1111/jth.14158_bb0040 article-title: Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia publication-title: Thromb Res doi: 10.1016/j.thromres.2010.09.004 – volume: 121 start-page: 396 year: 2003 ident: 10.1111/jth.14158_bb0015 article-title: Guidelines on fibrinogen assays publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2003.04256.x – ident: 10.1111/jth.14158_bb0055 – volume: 113 start-page: 154 year: 2015 ident: 10.1111/jth.14158_bb0045 article-title: Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey publication-title: Thromb Haemost doi: 10.1160/TH14-02-0161 |
| SSID | ssj0019520 |
| Score | 2.2804768 |
| Snippet | Essentials
Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied.
FIBPT‐d method overestimates fibrinogen in... Essentials Fibrinogen prothrombin time-derived (FIBPT-d) behavior in anticoagulated patients is under studied. FIBPT-d method overestimates fibrinogen in... BackgroundThe fibrinogen prothrombin time‐derived (FIBPT‐d) method with photo‐optical coagulometers is easy and economical. However, there are few reports on... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1626 |
| SubjectTerms | Antagonists Anticoagulants blood coagulation tests Coagulation dabigatran Fibrinogen fibrinogen analysis Heparin low molecular weight Molecular weight Patients Population studies Prothrombin rivaroxaban Thrombin Vitamin K |
| Title | The fibrinogen prothrombin time‐derived method is not useful in patients anticoagulated with low molecular weight heparins or rivaroxaban |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjth.14158 https://www.ncbi.nlm.nih.gov/pubmed/29790645 https://www.proquest.com/docview/2081323909 https://www.proquest.com/docview/2043174877 |
| Volume | 16 |
| WOSCitedRecordID | wos000440553400020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1538-7836 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0019520 issn: 1538-7933 databaseCode: DRFUL dateStart: 20030101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1538-7836 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0019520 issn: 1538-7933 databaseCode: WIN dateStart: 20030101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9NAEB2VFiEubfkoBNpoQBy4WEq8ttcrTogStQgihFqRm7W73lUqpTaynbZH7lz4jfwSZtcfomqRkDglUiaxlZm3-2Z3_R7AKyNoHiUmQaNfxIJIJYS5OJ0GXAmmlc5VIpQ3m-DzebpYiM8b8KZ_FqbVhxgW3Bwy_HjtAC5V_SfImyXBfBq7B33p1bkXfD2eDzsIIvaSjB7QVIOsUxXyp3j6b16fi24QzOt81U84s53_utVd2O54Jr5tC-MBbJjiIdz71O2kP4IfVB9o3Xn_oqQaQqfXsKzKc2qU0fnN__r-M6fivDA5tibTeFZjUTa4ro1dr5DCOknWGik5VE_Sm9pTvFvaxVV5iee99S5e-gVYXBrneVjUWFZIvy2r8koqWTyG09n7k3dHQWfMEGhGHXNAaaS2zYaRZDn1G6HPt865tiqPDYtkQmQ4EqGyNtLhJFF6ahNrRWwTZSQRiD3YLMrCPAXkOtKx0KlInExOqKVNuIpVzq2d0MjLRvC6T1GmO9VyZ56xyobupVlm_s8dwcsh9Fsr1XFb0H6f56xDa52FxItYyMREjODF8DHhzG2eyMKUaxfjqBa1d3wET9r6GK4SCi6c7h_drC-Dv18--3By5N88-_fQ53CfWFranjrch82mWpsDuKsvmrO6GsMdvkjHsHX4ZXb6cewx8BsTnwrk |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NTxsxEB0BraCXfkKbAu2AOHBZKVnvl6VeKlQUWoh6CILbyvbaSiTYrXY30GPvXPiN_BLG3g8VtZUqcYuUSbzKzLPf2M57AHua0zpKTIJmv4B5gYwIc2Ey8mLJmZIqkxGXzmwinkyS83P-fQk-df-FafQh-g03iww3X1uA2w3p31FezwjnozBZhicBEQ1r3HB2NOnPEHjoRBkdpKkKWasr5O7xdB99uBr9QTEfMla35By-eNzDvoTnLdXEz01tvIIlnb-G1ZP2MP0N3FCJoLFX_vOCygitZMOsLC6pV0ZrOX_36zaj-rzSGTY-0zivMC9qXFSaxkUKa1VZK6T8UEkJ52tP8XZ3Fy-Ka7zs3Hfx2u3B4kxb28O8wqJE-m5RFj-FFPk6nB5-mR6MvdabwVOMmmaPMkmdm_EDwTJqOXyXcpXFysgs1CwQEfHhgPvSmED5w0iqkYmM4aGJpBbEITZgJS9y_Q4wVoEKuUp4ZJVyfCVMFMtQZrExQ5p82QD2uxylqhUut_4ZF2nfwNSz1P24A9jtQ380ah1_C9rqEp22gK1Sn6gR8xkf8gHs9G8T1Oz5ich1sbAxlm1RhxcP4G1TIP0oPo-5lf6jh3V18O_h06_TsXvx_v9DP8LaeHpynB4fTb5twjMibUlzCXELVupyobfhqbqq51X5wUHgHv0rDHo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3RpUK9AP2gbAvttOqhl0i7cb4scamAFW3pClUgcYtsx9YiLQlKssCRey_9jf0ljJ0PgShSpd4iZXYT7cyz39je9wA-aU7zKDEJGv0C5gUyIsyFydiLJWdKqkxGXDqziXg6TU5P-dES7HT_hWn0IfoFN4sMN15bgOuLzNxFeT0jnI_D5AksB9ZEZgDLez8nJ4f9LgIPnSyjAzXVIWuVhdxJnu7D9-ejByTzPmd1k85k7f9edx1WW7KJX5rqeA5LOn8BKz_a7fSX8IuKBI099J8XVEhoRRtmZXFO3TJa0_k_N78zqtBLnWHjNI1nFeZFjYtKm8UcKazVZa2QMkRFJZyzPcXb9V2cF1d43vnv4pVbhcWZtsaHeYVFifTdoiyuhRT5KziZ7B_vHnitO4OnGLXNHuWSejfjB4Jl1HT4Lukqi5WRWahZICJixAH3pTGB8keRVGMTGcNDE0ktiEVswCAvcr0JGKtAhVwlPLJaOb4SJoplKLPYmBENv2wIn7scpaqVLrcOGvO0b2HqWep-3CF87EMvGr2OvwVtdYlOW8hWqU_kiPmMj_gQPvS3CWx2B0XkuljYGMu3qMeLh_C6KZD-KT6PuRX_o5d1dfD449Nvxwfu4s2_h76HlaO9SXr4dfr9LTwj1pY0pxC3YFCXC70NT9VlfVaV71oM3AKvkQ0j |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+fibrinogen+prothrombin+time%E2%80%90derived+method+is+not+useful+in+patients+anticoagulated+with+low+molecular+weight+heparins+or+rivaroxaban&rft.jtitle=Journal+of+thrombosis+and+haemostasis&rft.au=Duboscq%2C+C.&rft.au=Martinuzzo%2C+M.+E.&rft.au=Ceresetto%2C+J.&rft.au=Lopez%2C+M.&rft.date=2018-08-01&rft.issn=1538-7933&rft.eissn=1538-7836&rft.volume=16&rft.issue=8&rft.spage=1626&rft.epage=1631&rft_id=info:doi/10.1111%2Fjth.14158&rft.externalDBID=10.1111%252Fjth.14158&rft.externalDocID=JTH14158 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7933&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7933&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7933&client=summon |